Modular Medical Prices Direct Offering of 750,000 Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy MODD?
Source: Yahoo Finance
- Offering Size: Modular Medical announced a direct offering of 750,000 shares at $4.50 per share, with gross proceeds estimated at approximately $3.4 million, which will provide crucial funding for the company's operations and R&D initiatives.
- Underwriter Role: Maxim Group LLC is acting as the sole placement agent for this offering, ensuring professionalism and compliance throughout the process, thereby enhancing investor confidence in the company.
- Registration Statement Background: The offering is conducted under a shelf registration statement on Form S-3 that became effective on May 22, 2025, indicating the company's compliance and transparency in the capital markets, which helps attract more investors.
- Market Outlook: Modular Medical aims to launch next-generation insulin delivery technology, focusing on improving the medication experience for diabetes patients, which is expected to drive long-term growth for the company in the medical device market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MODD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MODD
About MODD
Modular Medical, Inc. is a development-stage medical device company. The Company is focused on the design, development, and commercialization of insulin pumps using technology to increase pump adoption in the diabetes marketplace. The Company's product seeks to serve both the type 1 and type 2 diabetes markets for those individuals requiring insulin. MODD1, its product, is a high-precision pump. MODD1's features include two parts - one reusable, one disposable - snap together to form the working system; one button interface; 90-day reusable, three-day disposable; disposable portion removable at any time from an adhesive-backed retainer, which remains in place, and no external controller required, no charging and no battery replacement. MODD1 comes with a variety of methods for the patient to wear the pump. Options include a baseplate with adhesive for attaching to the body that has features for holding the pump to the patient, and overwraps to hold the product to the patient.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Modular Medical Prices Direct Offering of 750,000 Shares
- Offering Size: Modular Medical announced a direct offering of 750,000 shares at $4.50 per share, with gross proceeds estimated at approximately $3.4 million, which will provide crucial funding for the company's operations and R&D initiatives.
- Underwriter Role: Maxim Group LLC is acting as the sole placement agent for this offering, ensuring professionalism and compliance throughout the process, thereby enhancing investor confidence in the company.
- Registration Statement Background: The offering is conducted under a shelf registration statement on Form S-3 that became effective on May 22, 2025, indicating the company's compliance and transparency in the capital markets, which helps attract more investors.
- Market Outlook: Modular Medical aims to launch next-generation insulin delivery technology, focusing on improving the medication experience for diabetes patients, which is expected to drive long-term growth for the company in the medical device market.
See More
Modular Medical Secures FDA Clearance for Next-Gen Insulin Pump, Targeting $3 Billion Market
- FDA Clearance Milestone: Modular Medical's Pivot insulin pump has received FDA 510(k) clearance, marking a significant unlocking of commercial sales with initial customer shipments expected by Q2 2026, which notably reduces commercialization risks and opens a revenue growth pathway.
- Innovative Design Advantage: The Pivot pump features a first-of-its-kind removable tubeless design with a 3 mL replaceable reservoir, requiring no battery recharging and suitable for showering and sports, aimed at addressing the complexity and high costs associated with traditional insulin pumps to enhance patient adoption.
- Massive Market Potential: Approximately 70% of insulin-dependent adults remain on multiple daily injections, and the Pivot pump aims to attract this large
See More
Modular Medical Implements 1-for-30 Reverse Stock Split to Maintain Nasdaq Listing
- Reverse Stock Split Plan: Modular Medical has announced a 1-for-30 reverse stock split effective March 31, 2026, aimed at raising its share price to meet Nasdaq's $1 minimum bid requirement, thereby ensuring continued listing eligibility.
- Impact on Shares: Post-split, the company's outstanding shares will decrease from approximately 139.8 million to about 4.66 million, a significant reduction that is expected to enhance the per-share price and boost investor confidence in the stock.
- Market Reaction Expectations: By implementing the reverse stock split, Modular Medical anticipates improving its market performance and attracting more investor interest, particularly in light of the Nasdaq listing requirements it faces.
- Strategic Implications: This split is not only a regulatory compliance measure but may also create more favorable conditions for future financing and business expansion, thereby strengthening its competitive position in the medical device industry.
See More
MODULAR MEDICAL INC - WORKFORCE REDUCTION AFFECTS 20 JOBS, REPRESENTING 29% OF EMPLOYEES - SEC FILING
- Modular Medical Reductions: The implementation of modular medical reductions is projected to impact 20 positions, which represents 29% of the workforce in the sector.
- Workforce Implications: The reduction in positions highlights significant changes within the medical field, particularly affecting the staffing and operational capabilities of organizations.
See More
Comfort Systems Reports Strong Earnings Beat
- Earnings Beat: Comfort Systems reported earnings of $9.37 per share, surpassing the analyst consensus estimate of $6.75, indicating a significant improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $2.646 billion, exceeding the analyst consensus estimate of $2.337 billion, reflecting strong market demand and driving overall performance.
- Positive Stock Reaction: Comfort Systems shares jumped 4.6% to $1,436.25 in pre-market trading, indicating a favorable market response to the earnings report, which may attract more investor interest.
- Optimistic Market Outlook: The strong earnings data not only enhances the company's short-term stock price but also lays the groundwork for future growth, increasing market attractiveness for long-term investments in Comfort Systems.
See More
Plus Therapeutics Prices Public Offering, Raising $15 Million
- Financing Update: Plus Therapeutics announced the pricing of 39,473,684 units at $0.38 each, expecting to raise approximately $15 million, which will provide fresh capital to advance its precision diagnostics and radiopharmaceutical programs targeting central nervous system cancers.
- Market Performance: Connect Biopharma's stock rose 5.96% to $2.31 without any new news, reflecting ongoing investor interest in its lead candidate rademikibart's new mechanism of action data and strategic priorities for 2026.
- Sector Momentum: ABVC BioPharma's shares increased by 3.37% to $2.15, suggesting that investor interest may be driven by broader momentum in the biotech sector despite the absence of new corporate updates.
- Clinical Progress: Traws Pharma's stock rose 2.82% to $1.82 following its announcement of filing a U.S. IND application for tivoxavir marboxil, further supporting investor optimism around the company's pipeline.
See More
Modular Medical Prices Direct Offering of 750,000 Shares
- Offering Size: Modular Medical announced a direct offering of 750,000 shares at $4.50 per share, with gross proceeds estimated at approximately $3.4 million, which will provide crucial funding for the company's operations and R&D initiatives.
- Underwriter Role: Maxim Group LLC is acting as the sole placement agent for this offering, ensuring professionalism and compliance throughout the process, thereby enhancing investor confidence in the company.
- Registration Statement Background: The offering is conducted under a shelf registration statement on Form S-3 that became effective on May 22, 2025, indicating the company's compliance and transparency in the capital markets, which helps attract more investors.
- Market Outlook: Modular Medical aims to launch next-generation insulin delivery technology, focusing on improving the medication experience for diabetes patients, which is expected to drive long-term growth for the company in the medical device market.
See More
Modular Medical Secures FDA Clearance for Next-Gen Insulin Pump, Targeting $3 Billion Market
- FDA Clearance Milestone: Modular Medical's Pivot insulin pump has received FDA 510(k) clearance, marking a significant unlocking of commercial sales with initial customer shipments expected by Q2 2026, which notably reduces commercialization risks and opens a revenue growth pathway.
- Innovative Design Advantage: The Pivot pump features a first-of-its-kind removable tubeless design with a 3 mL replaceable reservoir, requiring no battery recharging and suitable for showering and sports, aimed at addressing the complexity and high costs associated with traditional insulin pumps to enhance patient adoption.
- Massive Market Potential: Approximately 70% of insulin-dependent adults remain on multiple daily injections, and the Pivot pump aims to attract this large
See More
Modular Medical Implements 1-for-30 Reverse Stock Split to Maintain Nasdaq Listing
- Reverse Stock Split Plan: Modular Medical has announced a 1-for-30 reverse stock split effective March 31, 2026, aimed at raising its share price to meet Nasdaq's $1 minimum bid requirement, thereby ensuring continued listing eligibility.
- Impact on Shares: Post-split, the company's outstanding shares will decrease from approximately 139.8 million to about 4.66 million, a significant reduction that is expected to enhance the per-share price and boost investor confidence in the stock.
- Market Reaction Expectations: By implementing the reverse stock split, Modular Medical anticipates improving its market performance and attracting more investor interest, particularly in light of the Nasdaq listing requirements it faces.
- Strategic Implications: This split is not only a regulatory compliance measure but may also create more favorable conditions for future financing and business expansion, thereby strengthening its competitive position in the medical device industry.
See More
MODULAR MEDICAL INC - WORKFORCE REDUCTION AFFECTS 20 JOBS, REPRESENTING 29% OF EMPLOYEES - SEC FILING
- Modular Medical Reductions: The implementation of modular medical reductions is projected to impact 20 positions, which represents 29% of the workforce in the sector.
- Workforce Implications: The reduction in positions highlights significant changes within the medical field, particularly affecting the staffing and operational capabilities of organizations.
See More
Comfort Systems Reports Strong Earnings Beat
- Earnings Beat: Comfort Systems reported earnings of $9.37 per share, surpassing the analyst consensus estimate of $6.75, indicating a significant improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $2.646 billion, exceeding the analyst consensus estimate of $2.337 billion, reflecting strong market demand and driving overall performance.
- Positive Stock Reaction: Comfort Systems shares jumped 4.6% to $1,436.25 in pre-market trading, indicating a favorable market response to the earnings report, which may attract more investor interest.
- Optimistic Market Outlook: The strong earnings data not only enhances the company's short-term stock price but also lays the groundwork for future growth, increasing market attractiveness for long-term investments in Comfort Systems.
See More
Plus Therapeutics Prices Public Offering, Raising $15 Million
- Financing Update: Plus Therapeutics announced the pricing of 39,473,684 units at $0.38 each, expecting to raise approximately $15 million, which will provide fresh capital to advance its precision diagnostics and radiopharmaceutical programs targeting central nervous system cancers.
- Market Performance: Connect Biopharma's stock rose 5.96% to $2.31 without any new news, reflecting ongoing investor interest in its lead candidate rademikibart's new mechanism of action data and strategic priorities for 2026.
- Sector Momentum: ABVC BioPharma's shares increased by 3.37% to $2.15, suggesting that investor interest may be driven by broader momentum in the biotech sector despite the absence of new corporate updates.
- Clinical Progress: Traws Pharma's stock rose 2.82% to $1.82 following its announcement of filing a U.S. IND application for tivoxavir marboxil, further supporting investor optimism around the company's pipeline.
See More
